日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML

BRG1/BRM抑制剂联合BET抑制剂或地西他滨治疗高危MECOM重排急性髓系白血病疗效显著。

期刊:Hemasphere
影响因子:14.6
doi:10.1002/hem3.70289
Fiskus, Warren; Mill, Christopher P; Piel, Jessica; Collins, Mike; Hentemann, Murphy; Cuglievan, Branko; Birdwell, Christine E; Das, Kaberi; Davis, John A; Hou, Hanxi; Jain, Antrix; Malovannaya, Anna; Flores, Lauren B; Kadia, Tapan M; Daver, Naval; Sasaki, Koji; Takahashi, Koichi; Hammond, Danielle; Wang, Jian; Loghavi, Sanam; Su, Xiaoping; DiNardo, Courtney D; Delwel, Ruud; Bhalla, Kapil N
白血病
BRM
发表日期：2026
文献求助 收藏

Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML

更正：基于BET抑制剂的联合疗法靶向MECOM重排(r) AML中的新型依赖性

期刊:Leukemia
影响因子:13.4
doi:10.1038/s41375-026-02911-8
Birdwell, Christine E; Fiskus, Warren; Mill, Christopher P; Kadia, Tapan M; Daver, Naval; DiNardo, Courtney D; Sasaki, Koji; Davis, John A; Das, Kaberi; Hou, Hanxi; Jain, Antrix; Malovannaya, Anna; Flores, Lauren B; Pourebrahim, Rasoul; Yuan, Selina; Su, Xiaoping; Ceribelli, Michele; Bhalla, Kapil N
发表日期：2026
文献求助 收藏

BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML

基于BET抑制剂的联合疗法靶向MECOM重排(r) AML中的新型依赖性

期刊:Leukemia
影响因子:13.4
doi:10.1038/s41375-025-02842-w
Birdwell, Christine E; Fiskus, Warren; Mill, Christopher P; Kadia, Tapan M; Daver, Naval; DiNardo, Courtney D; Sasaki, Koji; Davis, John A; Das, Kaberi; Hou, Hanxi; Jain, Antrix; Malovannaya, Anna; Flores, Lauren B; Pourebrahim, Rasoul; Yuan, Selina; Su, Xiaoping; Ceribelli, Michele; Bhalla, Kapil N
发表日期：2026
文献求助 收藏

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.

CDK7抑制剂联合疗法对转化为AML的骨髓增生性肿瘤的临床前疗效

期刊:Blood
影响因子:23.1
doi:10.1182/blood.2024026388
Fiskus Warren, Mill Christopher P, Bose Prithviraj, Masarova Lucia, Pemmaraju Naveen, Dunbar Andrew, Birdwell Christine E, Davis John A, Das Kaberi, Hou Hanxi, Manshouri Taghi, Jain Antrix, Malovannaya Anna, Philip Kevin, Alhamadani Noor, Matthews Alicia, Lin Katie, Flores Lauren B, Loghavi Sanam, DiNardo Courtney, Su Xiaoping, Rampal Raajit K, Bhalla Kapil N
肿瘤
发表日期：2025
文献求助 收藏

Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations

BRG1/BRM与FLT3抑制剂联合治疗对FLT3突变型AML细胞具有优异的临床前疗效

期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-025-01251-7
Fiskus, Warren; Mill, Christopher P; Piel, Jessica; Collins, Mike; Hentemann, Murphy; Cuglievan, Branko; Birdwell, Christine E; Das, Kaberi; Hou, Hanxi; Davis, John A; Jain, Antrix; Malovannaya, Anna; Kadia, Tapan M; Daver, Naval; Sasaki, Koji; Takahashi, Koichi; Hammond, Danielle; Reville, Patrick K; Flores, Lauren B; Loghavi, Sanam; Su, Xiaoping; DiNardo, Courtney D; Bhalla, Kapil N
细胞生物学
BRM
FLT3
发表日期：2025
文献求助 收藏

Correction: Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1

更正：靶向表观遗传共依赖性可增强 Menin 抑制剂在 MLL1 重排或 NPM1 突变型 AML 中的抗 AML 疗效

期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-025-01306-9
Fiskus, Warren; Mill, Christopher P; Birdwell, Christine; Davis, John A; Das, Kaberi; Boettcher, Steffen; Kadia, Tapan M; DiNardo, Courtney D; Takahashi, Koichi; Loghavi, Sanam; Soth, Michael J; Heffernan, Tim; McGeehan, Gerard M; Ruan, Xinjia; Su, Xiaoping; Vakoc, Christopher R; Daver, Naval; Bhalla, Kapil N
Menin
NPM
表观遗传
MLL1
发表日期：2025
文献求助 收藏

Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase

tasquinimod联合疗法治疗晚期骨髓增生性肿瘤急变期患者的临床前疗效

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2025016898
Fiskus, Warren; Masarova, Lucia; Mill, Christopher P; Birdwell, Christine E; Das, Kaberi; Hou, Hanxi; Davis, John A; Jain, Antrix; Malovannaya, Anna; Manshouri, Taghi; Dunbar, Andrew; Sharma, Surbhi; Kadia, Tapan M; DiNardo, Courtney D; Bose, Prithviraj; Pemmaraju, Naveen; Loghavi, Sanam; Su, Xiaoping; Rampal, Raajit K; Törngren, Marie; Bhalla, Kapil N
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

A new cure model accounting for longitudinal data and flexible patterns of hazard ratios over time

一种新的治愈模型，考虑了纵向数据和随时间变化的风险比的灵活模式

期刊:Statistical Methods in Medical Research
影响因子:1.9
doi:10.1177/09622802251320793
Xie, Can; Huang, Xuelin; Li, Ruosha; Shen, Yu; Short, Nicholas J; Bhalla, Kapil N
发表日期：2025
文献求助 收藏

Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1

奥马西他滨和维奈托克用于治疗复发/难治性急性髓系白血病或伴有突变 RUNX1 的骨髓增生异常综合征

期刊:
影响因子:
doi:10.1016/j.bneo.2025.100145
DiNardo, Courtney D; Jen, Wei-Ying; Montalban-Bravo, Guillermo; Wang, Xuemei; Loghavi, Sanam; Lavu, Sravanthi; Short, Nicholas J; Chien, Kelly; Issa, Ghayas C; Pemmaraju, Naveen; Yilmaz, Musa; Andreeff, Michael; Borthakur, Gautam; Kadia, Tapan M; Daver, Naval G; Garcia-Manero, Guillermo; Mill, Christopher P; Su, Xiaoping; Fiskus, Warren; Bhalla, Kapil N
白血病
RUNX1
发表日期：2025
文献求助 收藏

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

BRG1/BRM抑制剂靶向AML干细胞，与BET或menin抑制剂联合使用时，在临床前疗效显著优于其他抑制剂。

期刊:Blood
影响因子:23.1
doi:10.1182/blood.2023022832
Fiskus, Warren; Piel, Jessica; Collins, Mike; Hentemann, Murphy; Cuglievan, Branko; Mill, Christopher P; Birdwell, Christine E; Das, Kaberi; Davis, John A; Hou, Hanxi; Jain, Antrix; Malovannaya, Anna; Kadia, Tapan M; Daver, Naval; Sasaki, Koji; Takahashi, Koichi; Hammond, Danielle; Reville, Patrick K; Wang, Jian; Loghavi, Sanam; Sen, Rwik; Ruan, Xinjia; Su, Xiaoping; Flores, Lauren B; DiNardo, Courtney D; Bhalla, Kapil N
细胞生物学
发育与干细胞
BRM
干细胞
发表日期：2024
文献求助 收藏